Jonathan Kluger1, Alicia Roy2, Herta H Chao3. 1. Yale University School of Medicine, 367 Cedar Street, New Haven, CT, 06510, USA. 2. Yale Comprehensive Cancer Center & VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT, 06516, USA. 3. Yale Comprehensive Cancer Center & VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT, 06516, USA. herta.chao@yale.edu.
Abstract
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is widely used in prostate cancer. Interest in assessing how ADT impacts cognition is growing. RECENT FINDINGS: Studies in animals and humans suggest that androgens may affect cognitive function. However, extant studies utilizing common neurocognitive tests have not consistently demonstrated ADT-induced cognitive impairment. Retrospective analyses investigating the association between ADT and risk of dementia in large electronic patient databases have also produced conflicting results. There is only limited data on ADT-induced changes in the brain as detected by functional imaging. It remains unclear whether cognitive deficits can occur in a patient undergoing ADT. Commonly used neurocognitive tests may not be optimal for detection of more subtle but clinically relevant cognitive impairment. While large electronic patient databases are attractive sources of information, their heterogeneity, complexity, and potential reporting biases can be a challenge. Better tools are needed to assess the cognitive impact of ADT prospectively.
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is widely used in prostate cancer. Interest in assessing how ADT impacts cognition is growing. RECENT FINDINGS: Studies in animals and humans suggest that androgens may affect cognitive function. However, extant studies utilizing common neurocognitive tests have not consistently demonstrated ADT-induced cognitive impairment. Retrospective analyses investigating the association between ADT and risk of dementia in large electronic patient databases have also produced conflicting results. There is only limited data on ADT-induced changes in the brain as detected by functional imaging. It remains unclear whether cognitive deficits can occur in a patient undergoing ADT. Commonly used neurocognitive tests may not be optimal for detection of more subtle but clinically relevant cognitive impairment. While large electronic patient databases are attractive sources of information, their heterogeneity, complexity, and potential reporting biases can be a challenge. Better tools are needed to assess the cognitive impact of ADT prospectively.
Authors: Po H Lu; Donna A Masterman; Ruth Mulnard; Carl Cotman; Bruce Miller; Kristine Yaffe; Erin Reback; Verna Porter; Ronald Swerdloff; Jeffrey L Cummings Journal: Arch Neurol Date: 2005-12-12
Authors: Andrew Wilcox; Molly L Carnes; Timothy D Moon; Renee Tobias; Heather Baade; Emily Stamos; Mary E Elliott Journal: Ann Pharmacother Date: 2006-11-28 Impact factor: 3.154
Authors: H J Green; K I Pakenham; B C Headley; J Yaxley; D L Nicol; P N Mactaggart; C E Swanson; R B Watson; R A Gardiner Journal: BJU Int Date: 2004-05 Impact factor: 5.588
Authors: S D Moffat; A B Zonderman; E J Metter; C Kawas; M R Blackman; S M Harman; S M Resnick Journal: Neurology Date: 2004-01-27 Impact factor: 9.910
Authors: Maxine Sun; Alexander P Cole; Nawar Hanna; Lorelei A Mucci; Donna L Berry; Shehzad Basaria; David K Ahern; Adam S Kibel; Toni K Choueiri; Quoc-Dien Trinh Journal: J Urol Date: 2018-02-02 Impact factor: 7.450
Authors: Herta H Chao; Sien Hu; Jaime S Ide; Edward Uchio; Sheng Zhang; Michal Rose; John Concato; Chiang-Shan R Li Journal: PLoS One Date: 2013-08-19 Impact factor: 3.240
Authors: Cecilie R Buskbjerg; Ali Amidi; Simon Buus; Claus H Gravholt; S M Hadi Hosseini; Robert Zachariae Journal: Prostate Cancer Prostatic Dis Date: 2021-06-04 Impact factor: 5.554
Authors: Gregory L Branigan; Georgina Torrandell-Haro; Maira Soto; Edward P Gelmann; Francesca Vitali; Kathleen E Rodgers; Roberta Diaz Brinton Journal: Cancer Med Date: 2022-03-16 Impact factor: 4.711